Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 2, 2016, Pages 206-213

  Karalliedde, Janaka ^a   Gnudi, Luigi ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes; Insulin resistance; Kidney disease

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; LEPTIN;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; GENE MUTATION; HNF1B GENE; HUMAN; HYPERGLYCEMIA; IDIOPATHIC DISEASE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; KCNJ11 GENE; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; BLOOD; COMPLICATION; DIABETIC NEPHROPATHIES; MALE; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; INSULIN; INSULIN RESISTANCE; MALE;

EID: 84964861603     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu405     Document Type: Review

References (70)

1. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795
2. Halban PA, Polonsky KS, Bowden DWet al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab 2014; 99: 1983-1992
3. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl 1): S81-S90
5. Imkampe AK, Gulliford MC. Trends in type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991-2008. Diabet Med 2011; 28: 811-814
6. Solis-Herrera C, Triplitt CL, Lynch JL. Nephropathy in youth and young adults with type 2 diabetes. Curr Diab Rep 2014; 14: 456
7. Dart AB, Sellers EA, Martens PJ et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012; 35: 1265-1271
8. Balasubramanyam A, Garza G, Rodriguez L et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006; 29: 2575-2579
9. Mauvais-Jarvis F, Sobngwi E, Porcher R et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes 2004; 53: 645-653
10. Umpierrez GE. Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Diabetes Care 2006; 29: 2755-2757
11. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011; 343: d6044
12. Steele AM, Shields BM, Wensley KJ et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014; 311: 279-286
13. Heidet L, Decramer S, Pawtowski A et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin J Am Soc Nephrol 2010; 5: 1079-1090
14. Faguer S, Decramer S, Chassaing N et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int 2011; 80: 768-776
15. Jeha GS, VenkateshMP, Edelen RCet al. Neonatal diabetes mellitus: patient reports and review of current knowledge and clinical practice. J Pediatr Endocrinol Metab 2005; 18: 1095-1102
16. Pearson ER, Flechtner I, Njolstad PR et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. N Engl J Med 2006; 355: 467-477
17. Naing A, Kenchaiah M, Krishnan B et al. Maternally inherited diabetes and deafness (MIDD): diagnosis and management. J Diabetes Complications 2014; 28: 542-546
18. Maassen JA, LM TH, Van Essen E et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 2004; 53(Suppl 1): S103-S109
19. Tuomi T, Santoro N, Caprio S et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014; 383: 1084-1094
20. Adler AI, Shine BS, Chamnan P et al. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008; 31: 1789-1794
21. Adler AI, Shine B, Haworth C et al. Hyperglycemia and death in cystic fibrosis- related diabetes. Diabetes Care 2011; 34: 1577-1578
22. Creighton Mitchell T, McClain DA. Diabetes and hemochromatosis. Curr Diab Rep 2014; 14: 488
23. Farmer A. Use of HbA1c in the diagnosis of diabetes. BMJ 2012; 345: e7293
24. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
25. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006; 12(Suppl 1): 34-41
26. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
28. Yip J, Mattock M, Sethi M et al. Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria. Lancet 1993; 341: 369-370
29. Yip J, Mattock MB, Morocutti A et al. Insulin resistance in insulindependent diabetic patients with microalbuminuria. Lancet 1993; 342: 883-887
30. Parvanova AI, Trevisan R, Iliev IP et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006; 55: 1456-1462
31. Dwyer JP, Parving HH, Hunsicker LG et al. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study. Cardiorenal Med 2012; 2: 1-10
32. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27: 195-200
33. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52: 1036-1040
34. Lorenzo C, Nath SD, Hanley AJ et al. Relation of low glomerular filtration rate to metabolic disorders in individuals without diabetes and with normoalbuminuria. Clin J Am Soc Nephrol 2008; 3: 783-789
35. Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012; 3: 1-6
36. Mogensen CE. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986; 46: 201-206
37. Mogensen CE. Glomerular filtration rate and renal plasma flow in shortterm and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest 1971; 28: 91-100
38. Lurbe E, Redon J, Kesani A et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797-805
39. Poulsen PL, HansenKW, Mogensen CE. Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients. Diabetes 1994; 43: 1248-1253
40. Gnudi L, Thomas SM, Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. JAmSoc Nephrol 2007; 18: 2226-2232
41. Huber TB, Hartleben B, Winkelmann K et al. Loss of podocyte aPKClambda/ iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol 2009; 20: 798-806
42. De Vriese AS, Stoenoiu MS, ElgerMet al. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int 2001; 60: 202-210
43. Kagami S, Border WA, Miller DE et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437
44. Sharma K, Cook A, Smith M et al. TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 2005; 288: F1069-F1077
45. Anderson S, Vora JP. Current concepts of renal hemodynamics in diabetes. J Diabetes Complications 1995; 9: 304-307
46. Raij L. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens 2005; 18(4 Pt 2): 95S-99S
47. Maddox DA, Brenner BM. Glomerular ultrafiltration. In: Brenner BM, Rector FC, Jr (eds). The Kidney. Philadelphia:W. B. Saunders Company, 2000, pp. 319-374
48. Arima S, Ito S. The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1966-1969
49. Trevisan R, Bruttomesso D, Vedovato M et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes 1998; 47: 1347-1353
50. Vedovato M, Lepore G, Coracina A et al. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia 2004; 47: 300-303
51. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014; 63: 1228-1237
52. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434
53. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597
54. Shimabukuro M, Higa N, Asahi T et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-3240
55. Deng G, Long Y, Yu YR et al. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond) 2010; 34: 165-171
56. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009; 76: 145-148
57. Thorn LM, Forsblom C, Fagerudd J et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024
58. Christou GA, Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 2014; 221: R49-R61
59. Fischer S, Hanefeld M, Haffner SM et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002; 39: 105-110
60. Hunley TE, Ma LJ, Kon V. Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens 2010; 19: 227-234
61. Wolf G, Hamann A, Han DC et al. Leptin stimulates proliferation and TGFbeta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int 1999; 56: 860-872
62. Otero M, Lago R, Lago F et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295-301
63. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801
64. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248
65. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-2800
66. Gnudi L. Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol Dial Transplant 2012; 27: 2642-2649
67. Welsh GI, Hale LJ, Eremina V et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12: 329-340
68. Coward RJ, Welsh GI, Yang J et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102
69. Coward RJ, Welsh GI, Koziell A et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007; 56: 1127-1135
70. Fornoni A. Proteinuria, the podocyte, and insulin resistance. N Engl J Med 2010; 363: 2068-2069